Navigation Links
Northwest Biotherapeutics Conducting Ovarian Cancer Clinical Trial With DCVax(R)-L at University of Pennsylvania
Date:12/27/2007

a very significant event for patients at the University of Pennsylvania and nationwide who are diagnosed with ovarian cancer. We are excited to work with Northwest Biotherapeutics on this cutting edge clinical trial, and to test the DCVax(R) platform on an additional cancer that carries a poor prognosis."

Dr. Carl June, the Penn sponsor on the trial, stated, "the combination of DCVax(R)-L for ovarian cancer with adoptive immunotherapy using T cells primed by DCVax(R)-L is an innovative approach that deserves testing in clinical trials."

"We are very pleased to add Ovarian cancer to the DCVax(R) platform, and to have Dr. George Coukos and Dr. Carl June lead this effort as the principal investigators for this clinical trial," stated Alton Boynton, President and Chief Executive Officer of Northwest Biotherapeutics. "Drs. Coukos and June are world renowned experts in immunotherapy and in ovarian cancer. They are playing a major role in the pioneering of novel cancer treatment strategies -- particularly by combining multiple different therapeutic approaches."

Ovarian cancer is the fourth leading cause of cancer death among women in the U.S. Approximately 22,400 new cases were diagnosed in the U.S. in 2006, and about 15,300 deaths occurred. In the majority of ovarian cancer cases, the disease has already reached late stage, and spread beyond the ovaries, before it is detected and diagnosed. After initial surgical removal of tumors, and treatment with currently available drugs, the median time to disease recurrence is 18 to 20 months. Recurrent disease is considered incurable and usually results in death, even with aggressive chemotherapy treatments. Accordingly, there is a major unmet medical need for new and more effective treatments for ovarian cancer -- especially recurrent ovarian cancer.

The DCVax(R) platform uses a patient's own tumor, surgically removed as part of the standard of care, to prepare a mix of their personal cancer biomarkers
'/>"/>

SOURCE Northwest Biotherapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
2. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
3. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
4. Clinical Studies of OvaRex in Advanced Ovarian Cancer Fail to Meet Primary Endpoint
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. Novel Technology Breaks Through Cancer Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Tianyin Pharmaceutical Co., Inc. (NYSE MKT: ... biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics ... the Company achieved the Public Notice (Gong Shi) ... of TPI,s Qionglai Facility (QLF) from the China ... period is a significant procedure of GMP certification ...
(Date:12/22/2014)... Mass. , Dec. 22, 2014 ... leading manufacturer of innovative dialysis products, announced today ... has cleared its System One™ to perform hemodialysis ... known as home nocturnal hemodialysis. NxStage,s® System One ... by the FDA for this indication. ...
(Date:12/22/2014)... a privately-held medical products and technologies company, today announced ... Officer of the company, effective December 22, 2014. ... Board of Directors of ConvaTec thanks Mr. Berger for ... years," said Magnus Lundberg , the Chairman of ... company is well positioned for the future."  The company ...
Breaking Medicine Technology:TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 3ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2
(Date:12/25/2014)... Among early stage breast cancer patients who undergo chemotherapy ... will eventually develop leukemia as a result of their ... from a review of more than 20,000 breast cancer ... that the risk for developing treatment-related leukemia, though low, ... "The frequency of bone marrow cancers such as leukemia ...
(Date:12/25/2014)... SmileStix ” was featured on NewsWatch as part of its ... on the iOS, Android, and Windows markets. Andrew Tropeano, a ... review and shared with viewers how this is an application ... goes, “A picture says a thousand words.” It’s true. There ... image, because each picture holds a unique and special meaning. ...
(Date:12/25/2014)... Parker & Sons, Inc. an industry leader ... quality regarding heating, cooling and plumbing services in the ... the “Queen of Clean” for impressive contractor services in ... over the years for providing outstanding quality customer service ... services for both homeowners and businesses. Linda Cobb, known ...
(Date:12/24/2014)... (PRWEB) December 24, 2014 Connie Casad, ... and functional medicine advocate with 30 years of practice ... to evaluate the health benefits of dietary detoxification. The ... new participants following excellent results from test patients who ... asked to explain her interest in conducting the study, ...
(Date:12/24/2014)... 2014 Dr. Vu Ho, a Dallas ... his practice and med-spa with the addition of new ... of cosmetic treatments and services. , “Silk Peel is ... says Dr. Ho. “As a result it can address ... sun spots, discolorations or blemishes.” , Similar to microdermabrasion, ...
Breaking Medicine News(10 mins):Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 3Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 3Health News:Dr. Vu Ho Expands Facial Plastic Surgery Practice to Include New Skin Care Treatment 2
... that the strongest risk factors for atrial fibrillation in both ... While hypertension is a well known risk factor for AF, ... later occurrence of AF has not been documented earlier". ... and is a major risk factor for heart failure (risk ...
... administering a common chemotherapy drug before bone tumors took ... once introduced, to seed and grow more easily. ... some cancers metastasize to bone, and could eventually result ... the Department of Periodontics and Oral Medicine at the ...
... (HealthDay News) -- People with HIV/AIDS are four times more ... the general population, a new study finds. The findings ... researchers from the University of California, San Francisco (UCSF). In ... the heart suddenly and unexpectedly stops beating. The researchers ...
... that looked at the hunger trends over a 10-year period ... more than one in seven, face the threat of hunger. ... reported that one in nine seniors faced the threat of ... agricultural and consumer economics and executive director of the National ...
... team of international scientists has made a significant breakthrough in ... of liver cancer. By identifying several new genes frequently mutated ... better understanding of how bile duct cancers develop. Their discovery ... Duct Cancer, or Cholangiocarcinoma, is a fatal cancer with a ...
... University researcher Julia Frugoli has received $132,769 as the ... the National Science Foundation to continue her study of ... to control their growth and development. The work ... of Agriculture, Forestry & Life Sciences, genetics and biochemistry ...
Cached Medicine News:Health News:Palpitations are predictive of future atrial fibrillation 2Health News:Palpitations are predictive of future atrial fibrillation 3Health News:'Fertilizing' bone marrow helps answer why some cancers spread to bones 2Health News:People With HIV at Higher Odds of Sudden Cardiac Death 2Health News:Great recession reflux amounts to more hunger among seniors 2Health News:Scientists make breakthrough in bile duct cancer with discovery of new gene mutations 2Health News:Scientists make breakthrough in bile duct cancer with discovery of new gene mutations 3Health News:Clemson professor awarded nearly $600,000 4-year grant to study language of plants 2
... & Nephew offers a wide variety of ... available in both partially threaded and fully ... are the 5.5 and 7.0 mm products. ... the surgeon's job a little easier. Ratchet ...
... Nailing System is one of the first ... for either an antegrade or a retrograde ... , ,Stryker Orthopaedics Trauma has now created ... together all the capabilities and benefits of ...
... Humeral Nail System has been designed to ... noninvasive treatments have historically failed to give ... blend of strength and flexibility. Ideally suited ... titanium alloy is twice that of stainless ...
... nailing techniques have largely replaced the use of plates ... The use of rods or pins in the forearm ... has been no way to lock the pins or ... a non-locked nail is back out of the implant. ...
Medicine Products: